Retatrutide statistics 2026

If you are using or thinking about a GLP-1 medicine for weight or diabetes, retatrutide sits in the 'what's next' category. It is designed to act on three hormone systems at once (GIP, GLP-1, and glucagon) rather than just one or two. That triple action has translated into striking trial numbers: people on higher doses lost weight in the same ballpark as some bariatric surgery results, at least over 11 months. But those numbers are from research, not everyday practice. Retatrutide is not yet approved, and the long-term safety, real-world routines, and insurance coverage are still unanswered. this guide walks through what the trials have actually shown, how those statistics translate into expected weight change for a typical person, and what questions you might ask your clinician or pharmacist when you hear about retatrutide or similar triple-agonist medicines.

The phase 2 obesity trial enrolled adults with obesity or overweight but without type 2 diabetes. They were randomized to retatrutide at different doses (1, 4, 8, or 12 mg) or placebo. Injections were given once weekly for 48 weeks, with some dose-escalation patterns to help with tolerability. The primary outcome was percent change in body weight at 24 weeks, with continued follow-up to 48 weeks. For someone already familiar with GLP-1 medicines, this trial looks similar in design to semaglutide or tirzepatide studies, but with higher average weight-loss percentages at the upper doses.

At 24 weeks (about 6 months), the 1 mg dose produced roughly 7.2% average weight loss, the 4 mg dose about 12.9%, the 8 mg dose about 17.3%, and the 12 mg dose about 17.5%. Placebo was around 1.6%. For a 240-pound person, 7.2% means about 17 pounds lost, 12.9% means about 31 pounds, and 17.3 to 17.5% means about 42 pounds. At 48 weeks (about 11 months), the 1 mg dose produced roughly 8.7% average weight loss, the 4 mg dose about 17.1%, the 8 mg dose about 22.8%, and the 12 mg dose about 24.2%. Placebo was around 2.1%. For the same 240-pound person, 8.7% means about 21 pounds, 17.1% means about 41 pounds, 22.8% means about 55 pounds, and 24.2% means about 58 pounds. The trial graphs showed that weight was still trending down at 48 weeks, suggesting that a plateau had not yet fully been reached.

At 48 weeks in the 12 mg group, 100% lost at least 5% of body weight, 93% lost at least 10%, and 83% lost at least 15%. In some breakdowns, around half lost at least 25%, and about one-quarter lost at least 30%. That is not a guarantee for everyone, but it means that in this carefully run trial, nearly all participants on the highest dose saw weight loss that most clinicians would call clinically significant, and many saw transformational loss.

A separate phase 2 study in people with type 2 diabetes found dose-dependent reductions in HbA1c and body weight. At 36 weeks, people on 12 mg had around 16.9% weight loss, with HbA1c reductions described as clinically meaningful. For a person starting at 230 pounds, 16.9% means about 39 pounds lost by roughly 8 to 9 months, alongside an improvement in blood sugar control. Exact HbA1c change depends on where a person starts (for example, going from 9.5% to 7% is more dramatic than from 7.5% to 6.5%), and the paper does not give a simple one-size-fits-all number you can safely apply to everyone.

Across obesity trials, the most common side effects were nausea, vomiting, diarrhea, and indigestion. These were dose-dependent, meaning higher doses tended to cause more of them. Other noted effects included increased heart rate, a rare serious pancreatitis case, and some cardiac arrhythmias (abnormal heart rhythms). These events were uncommon but serious enough that future trials and labeling will need to watch closely. Compared with today's GLP-1 drugs, the type of side effects looks familiar if you have used semaglutide or tirzepatide. The frequency and intensity at the highest retatrutide doses may be higher, given how much weight loss was achieved and how many pathways are being activated. No long-term MACE (major adverse cardiovascular events) data are available yet. MACE usually refers to non-fatal heart attack, non-fatal stroke, or cardiovascular death. To answer whether retatrutide is cardioprotective, neutral, or risky, we would need a dedicated cardiovascular outcomes trial that has not yet been completed or reported.

Retatrutide itself is not yet available, but you can still use its statistics to set expectations for possible future therapies, sharpen the way you track your own progress on today's GLP-1s, and prepare meaningful questions for your clinician. If retatrutide or a similar triple agonist becomes an option, here are practical things you would want to track or plan. Record starting weight and track weekly or every two weeks. Compare your trajectory to the percent ranges seen in trials (for example, aiming for 10 to 15% loss over 6 to 12 months if tolerated). Note any nausea, vomiting, diarrhea, constipation, or indigestion. Record timing versus injection day and dose changes. Bring this log to appointments; it helps your clinician adjust or consider alternative options. If you have diabetes, track home glucose readings and follow HbA1c changes at your lab visits. Ask how your change compares to typical GLP-1 responses. Watch for hypoglycemia (low blood sugar) if combined with insulin or sulfonylureas. Note any palpitations, chest pain, dizziness, or unusual shortness of breath. These symptoms matter when a medicine may influence heart rate and rhythm.

If retatrutide or similar triple agonists come up, you might ask: How does retatrutide weight loss compare to the GLP-1 I am on now? Ask for a direct comparison, for example, semaglutide typical 10 to 15% versus retatrutide 20% plus in trials. Is retatrutide being studied in people like me? Age range, BMI, presence of type 2 diabetes, heart disease, kidney disease, or other conditions. What do we know about long-term safety, especially heart and pancreas risks? Ask specifically about MACE data and pancreatitis findings as trials progress. If I switched from my current GLP-1 to a triple agonist, how would we manage side effects? Discuss dose-escalation plans and what would trigger a dose reduction or pause. What kind of weight loss would be realistic for me, given my health and history? Use trial percentages as a ceiling, not a guarantee, and adjust for your own situation. How would future pricing and coverage likely compare to my current medicine? Clinicians and pharmacists cannot predict exact prices, but they can explain how new drugs typically enter formularies and what copay tiers might look like.

this guide uses primary and near-primary medical sources wherever they exist. The NEJM phase 2 obesity trial and its PDF for exact trial design and weight-loss statistics. Eli Lilly press release for clear numeric summaries and trial structure. A type 2 diabetes paper in Diabetologie und Stoffwechsel for HbA1c and weight data in type 2 diabetes. Peer-reviewed reviews and reputable medical summaries on PubMed and 2 Minute Medicine for responder rates and safety interpretation. A Healio report for dose-by-dose percentages at specific time points. Steps taken: Identify primary trials involving retatrutide in obesity and type 2 diabetes. Extract main statistics: percent weight loss, responder rates, trial duration, dose arms, and side-effect frequencies from the NEJM paper, the Lilly release, and the diabetes article. Cross-check numbers against independent summaries (Healio, 2 Minute Medicine, PubMed reviews) to make sure the ranges match and no major details are misread. Translate percentages into practical weight changes for typical starting weights (for example, 240 pounds) so non-medical person can visualize impact. Flag missing information clearly, especially around FDA approval, price, insurance coverage, and long-term MACE data, instead of guessing. Avoid non-medical, speculative, or marketing sources, including peptide sellers, affiliate sites, and generic blogs. Where a number could not be verified in a primary source, it is either left out or labelled as needing specific data (for example, 'would require Lilly price release'). This keeps the statistics grounded in what has actually been measured and reported.